It's a bull market in stocks. The bond market is confirming that. Until we start to see evidence that suggests otherwise, we remain in the camp that this is a 'buy weakness' environment and not a time to be selling strength. To get 2018 going on a good note, Consumer Discretionary stocks broke out relative to the S&P500. This is one of the most important sectors in America and I believe it is still in a secular bull market.
Financials ripping to all-time highs is not something we see when stocks are in a downtrend. To the contrary, this is strong evidence of risk appetite for stocks. This seems to be something that is being underappreciated right now but I think is worth pointing to, again.
There are a lot of questions about the sustainability of the uptrend in stocks. Some might even say that stocks are "stretched" or have gone "too far too fast". But when you look at Financials, they're just getting going now. From many different perspectives, this sector has done nothing for a long time and is just now breaking out.
Long Precious Metals has been a big theme for us this year. I still think this is an area we need to be involved with and the weight-of-the-evidence is suggesting higher prices for the entire space.
Today I want to point out the recent breakout in Swiss Franc Futures. Historically there is a high positive correlation between this contract and the price of Gold. As we break out to new multi-year highs in Swissy, Gold looks likely to follow along:
I don't like how many oversold conditions have been hit in the major indexes and most sectors. I've tried my best to point out the stocks showing both relative strength and momentum. But there are an awful lot of charts I see where oversold conditions in momentum is a problem. So the question becomes, is a retest of the lows necessary for stocks to continue higher?
The market is never going to give us what we want. We have to take what the market gives us. Play the hand we're given, not the hand we wish we had. What worked in one market environment is not going to work in another. That's why all those filters fail so frequently, because you're trying to take something from the market instead of taking what it is giving us.
This week, a spike in volatility caused forced selling in stock index vehicles that trickled down to ETFs and individual stocks. We did not see any stress, however, in credit markets, currencies or any of the commodities like Crude Oil or Gold. This is further evidence that we want to continue be buyers of weakness, like we have been throughout all of last year and most of 2016. There will be periods where we want to be sellers of strength, but I don't believe that is the correct approach today.
If you've been following along, I try and go out of my way to discuss risk management techniques, tools and signals when the market gives them to us. Whenever I lay out a thesis, I like to talk about what the market should look like in the case that we are correct, while at the same time outlining what the environment would look like if we are wrong. The idea is to picture both scenarios and as the data comes in, try to identify which outcome we're in as quickly as possible.
It's not a secret that Emerging Markets were the big loser for a long time. Since peaking during the 2010-2011 time period, the underformance of anything EM, Mining and Natural Resources has been clear to all of us. Gold was a terrible investment, mining stocks, stocks in mining countries and others in that area had been the worst place to put your money for many years. Although still not in a full fledged parabolic rise, we've seen what appears like a healthy completion of a massive base.
To me, this is suggesting that the outperformance we've been seeing out of Emerging Markets is just getting started. The initial burst from early 2016 was more of a beta trade. This is when stocks as an asset class bottomed and the worst of the worst, emerging markets in this case, outperformed because of their higher volatility nature and the simple fact that, the harder the pounce, the more violent the bounce. We've gone nowhere the past 15 months since that initial thrust of the lows. Until now.
It's amazing how many people in this world completely ignore monthly charts. I never understood it. It's an exercise that only needs to be done once a month. It's not like eating healthy or working out that you have to do it consistently for it to work. This is 30 minutes per month! 30 minutes! 12 times a year. That's 6 hours of work that will be the most important and productive 6 hours of the entire year. Even if you have a short-term time horizon, all of these shorter-term trends come within the context of a much larger structural picture.
This weekend was our second annual Chart Summit. I still can't believe all the amazing feedback that continues to come in after this event. Thank you all from the bottom of my heart, both the presenters and the audience members. I didn't think we could make something even better than the original, but I think based on the responses, we may have actually pulled it off. Wow!
Our video production folks are hard at work putting all the videos together, but I've picked out the ones I did so I can share with all of you as soon as possible. The rest will be out this week.
It's hard to ignore a sector that is breaking out to new highs, especially when it's something that it hasn't done in a long time. Biotechnology has been a laggard for years. If we've wanted to be in healthcare, it certainly has not been in Biotech or Pharma, it's been Medical Equipment stocks. But it's 2018 and times are changing.
Today we're looking at breakouts in both the Equally-weighted Biotechnology Fund $XBI and the Cap-weighted Biotechnology Fund $IBB. Because of the very different composition of the two sector funds, we want to make sure to always watch the behavior of both. The $XBI tells a better story of the sector because it is not dominated by the big names like Amgen or Gilead. But at the same time, we're not going to just throw out the fact that $AMZN is a huge component of the Discretionary space, for example. So I think it's important to always keep an eye on both the cap-weighted and equally-weighted sector indexes.
Biotechnology has not been something you've been hearing me pound the table about for a long time. I was a huge Biotech bull in 2015, but this has not been something we've wanted to be involved with much since. The biggest reason is for the dramatic under-performance. The winning areas have been in Technology, Industrials and Financials, not Biotechnology. If we've wanted to be in healthcare at all it's been in the Medical Device and Equipment stocks, not Pharma or Biotech.
It's 2018 now and things are changing; sectors are rotating. We're seeing strength in Energy, Materials and really just Natural Resources in general. Canada and Australia breaking out finally points to strength in that area as well.
Today we're going to talk specifically about Biotechnology and if/where we want to be involved.